Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12)
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2018-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/133 |
| _version_ | 1797245182166433792 |
|---|---|
| author | V. T. Ivashkin I. G. Bakulin P. O. Bogomolov M. V. Matsiyevich N. I. Geyvandova P. V. Koroy S. V. Nedogoda O. A. Sablin L. G. Lenskaya Ye. V. Beloborodova A. A. Bagretsova R. A. Abdulkhakov M. F. Osipenko I. V. Osipova D. A. Pocheptsov Ye. V. Chumachek O. M. Khromtsova Ye. V. Kuzmicheva |
| author_facet | V. T. Ivashkin I. G. Bakulin P. O. Bogomolov M. V. Matsiyevich N. I. Geyvandova P. V. Koroy S. V. Nedogoda O. A. Sablin L. G. Lenskaya Ye. V. Beloborodova A. A. Bagretsova R. A. Abdulkhakov M. F. Osipenko I. V. Osipova D. A. Pocheptsov Ye. V. Chumachek O. M. Khromtsova Ye. V. Kuzmicheva |
| author_sort | V. T. Ivashkin |
| collection | DOAJ |
| first_indexed | 2024-03-08T09:21:57Z |
| format | Article |
| id | doaj.art-4131ff0071c74aa1ac7482e20794c338 |
| institution | Directory Open Access Journal |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| last_indexed | 2024-04-24T19:22:50Z |
| publishDate | 2018-08-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj.art-4131ff0071c74aa1ac7482e20794c3382024-03-25T16:53:07ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732018-08-01272344310.22416/1382-4376-2017-27-2-34-43133Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12)V. T. Ivashkin0I. G. Bakulin1P. O. Bogomolov2M. V. Matsiyevich3N. I. Geyvandova4P. V. Koroy5S. V. Nedogoda6O. A. Sablin7L. G. Lenskaya8Ye. V. Beloborodova9A. A. Bagretsova10R. A. Abdulkhakov11M. F. Osipenko12I. V. Osipova13D. A. Pocheptsov14Ye. V. Chumachek15O. M. Khromtsova16Ye. V. Kuzmicheva17The State Education Institution of Higher Professional Training The First Sechenov Moscow State Medical UniversityFederal government-financed healthcare institution «Moscow clinical scientific and practical center (MCSPC)»LLC «Tsentrosoyuz clinical hospital»LLC «Tsentrosoyuz clinical hospital»State educational government-financed institution of higher professional education «Stavropol state medical university»State educational government-financed institution of higher professional education «Stavropol state medical university»The State educational institution of higher education «Volgograd state medical university»; Federal government-financed healthcare institution «Volgograd regional hospital #3»The Federal state institute of public health «The Nikiforov Russian Center of Emergency and Radiation Medicine»Tomsk region State autonomous healthcare institution «Tomsk regional hospital»The State educational institution of higher education «Siberian State Medical University»State educational government-financed healthcare institution «Semashko Northern medical clinical center»The State educational institution of higher education «Kazan State Medical University»The State educational institution of higher education «Novosibirsk state medical university»Non-governmental healthcare institution «Barnaul station sectional hospital»Federal government-financed healthcare institution «Volgograd regional hospital #3»The State educational institution of higher education «Volgograd state medical university»The State educational institution of higher education «Ural state medical university»Municipal government-financed healthcare institution «Central municipal hospital #7»https://www.gastro-j.ru/jour/article/view/133фосфогливгепатопротекторнеалкогольная жировая болезнь печенивоспалениефиброзкачество жизни |
| spellingShingle | V. T. Ivashkin I. G. Bakulin P. O. Bogomolov M. V. Matsiyevich N. I. Geyvandova P. V. Koroy S. V. Nedogoda O. A. Sablin L. G. Lenskaya Ye. V. Beloborodova A. A. Bagretsova R. A. Abdulkhakov M. F. Osipenko I. V. Osipova D. A. Pocheptsov Ye. V. Chumachek O. M. Khromtsova Ye. V. Kuzmicheva Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12) Российский журнал гастроэнтерологии, гепатологии, колопроктологии фосфоглив гепатопротектор неалкогольная жировая болезнь печени воспаление фиброз качество жизни |
| title | Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12) |
| title_full | Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12) |
| title_fullStr | Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12) |
| title_full_unstemmed | Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12) |
| title_short | Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12) |
| title_sort | efficacy and safety of glycyrrhizic acid combined to essential phospholipids phosphogliv at non alcoholic fatty liver disease results of multicenter double blind randomized placebo controlled post registration clinical study iv phase gepard phg m2 p02 12 |
| topic | фосфоглив гепатопротектор неалкогольная жировая болезнь печени воспаление фиброз качество жизни |
| url | https://www.gastro-j.ru/jour/article/view/133 |
| work_keys_str_mv | AT vtivashkin efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT igbakulin efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT pobogomolov efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT mvmatsiyevich efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT nigeyvandova efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT pvkoroy efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT svnedogoda efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT oasablin efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT lglenskaya efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT yevbeloborodova efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT aabagretsova efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT raabdulkhakov efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT mfosipenko efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT ivosipova efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT dapocheptsov efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT yevchumachek efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT omkhromtsova efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 AT yevkuzmicheva efficacyandsafetyofglycyrrhizicacidcombinedtoessentialphospholipidsphosphoglivatnonalcoholicfattyliverdiseaseresultsofmulticenterdoubleblindrandomizedplacebocontrolledpostregistrationclinicalstudyivphasegepardphgm2p0212 |